Loading
Life sciences · Journal article
Issues of Reconstructive and Plastic Surgery · August 11, 2026
Encouraging direction, but not yet definitive.
This prospective non-randomized comparative study of 36 patients undergoing biliopancreatic diversion with or without a novel anti-reflux sphincter technique reports that the new reconstructive stage achieved greater excess weight loss (78.7% vs. 72.2%), faster T2DM remission (100% in both groups, but earlier medication discontinuation in the intervention arm), and higher quality of life scores (8.5 vs. 7.0 points). While the results are consistent with clinical benefit and the endpoints are patient-meaningful, the small non-randomized design and lack of long-term follow-up limit generalizability and evidence strength.
Prospective comparative non-randomized cohort study. 36 patients with morbid obesity; 20 had baseline type 2 diabetes mellitus diagnosis; enrolled between 2014 and 2024.. Intervention: Open biliopancreatic diversion with Roux-en-Y anastomosis plus original anti-reflux sphincter mechanism at the gastrojejunal anastomosis.. Compared with: Standard open biliopancreatic diversion with Roux-en-Y anastomosis without restoration of anastomotic occlusive function.. n = 36.
Excess weight loss was higher in the main group: 78.7% vs. 72.2% (p = 0.001) Fat mass reduction more pronounced in main group: 22.5% vs. 24.2% (p = 0.023) Type 2 diabetes remission achieved in 100% of baseline diabetic patients (n = 20); main group discontinued insulin and metformin 1–2 months earlier
Type 2 diabetes remission achieved in 100% of baseline diabetic patients (n = 20); main group discontinued insulin and metformin 1–2 months earlier
The novel anti-reflux sphincter technique appears to improve post-operative weight loss, diabetes remission timing, and patient-reported quality of life compared to standard BPD. However, the non-randomized design and modest sample size mean these results should be confirmed in a larger, prospective randomized trial before adoption into routine surgical practice.
A sound prospective comparative study with clinically relevant endpoints (weight loss, diabetes remission, quality of life) and modest sample size, showing superiority of a novel surgical technique, but limited by non-randomized design and single-centre nature.
As stated by the source record.
Quoted from the source exactly as published.
The novel anti-reflux sphincter technique appears to improve post-operative weight loss, diabetes remission timing, and patient-reported quality of life compared to standard BPD. However, the non-randomized design and modest sample size mean these results should be confirmed in a larger, prospective randomized trial before adoption into routine surgical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Purpose of a study: to perform a correlation analysis of the effect of a new reconstructive stage of biliopancreatic diversion on body composition, type 2 diabetes mellitus (T2DM) remission, and quality of life in patients with morbid obesity. Material and Methods. This prospective comparative non-randomized study included 36 patients with morbid obesity who underwent open biliopancreatic diversion with a Roux-en-Y anastomosis between 2014 and 2024. The main group ( n = 22) comprised patients in whom the surgeons created an anti-reflux sphincter mechanism at the gastrojejunal anastomosis using an original technique; the control group ( n = 14) comprised patients who underwent standard BPD without restoration of the anastomotic occlusive function. The investigators assessed body composition by bioelectrical impedance analysis, metabolic markers, T2DM status, and quality of life using an integral 10-point visual analogue scale at 12 months postoperatively. To identify relationships among body composition indices, metabolic markers, eating behavior parameters, and quality of life, the team applied Spearman's rank correlation analysis, which allowed them to establish not only the statistical significance of intergroup differences but also the direction and strength of associations between clinical and patient-reported outcomes. Results. The main group achieved a higher percentage of excess weight loss (78.7% vs. 72.2%; p = 0.001) and a more pronounced reduction in fat mass (22.5% vs. 24.2%; p = 0.023), while preserving active cell mass. All patients with a baseline T2DM diagnosis ( n = 20, 100%) achieved complete remission, and the main group discontinued insulin and metformin 1–2 months earlier than the control group. Quality of life scores were higher in the main group (8.5 vs. 7.0 points; p < 0.001). The researchers found a strong negative correlation between quality of life and fat mass percentage (ρ = –0.68; p < 0.001) and glycated hemoglobin (ρ = –0.64; p < 0.001), and a strong positive correlation with active cell mass (ρ = 0.61; p < 0.001). Conclusion. The formation of new reconstructive stages of BPD improves the metabolic profile due to a significant reduction in muscle mass while maintaining active cellular mass, accelerates the remission of type 2 diabetes and improves the quality of life of patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.